Brief: Fusion Antibodies Says Revenues For FY2024 Expected To Be Significantly Weighted Towards H2

Fusion Antibodies

04/12/2023 07:17

Dec 4 (Reuters) - Fusion Antibodies PLC  FAB.L :
    * REVENUES FOR FY2024 ARE EXPECTED TO BE SIGNIFICANTLY
WEIGHTED
TOWARDS SECOND HALF OF FINANCIAL YEAR

Source text for Eikon:  ID:nRSD4785Va 
Further company coverage:  FAB.L 

 ((Reuters.Briefs@thomsonreuters.com;))